Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial

Creative Commons License

Wong K. S. L. , Amarenco P., Albers G. W. , Denison H., Easton J. D. , Evans S. R. , ...Daha Fazla

STROKE, cilt.49, ss.1678-1685, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 49 Konu: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1161/strokeaha.118.020553
  • Dergi Adı: STROKE
  • Sayfa Sayıları: ss.1678-1685


Background and Purpose SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). Aspirin intake before randomization could enhance the effect of ticagrelor by conferring dual antiplatelet effect during a high-risk period for subsequent stroke. Therefore, we explored the efficacy and safety of ticagrelor versus aspirin in the patients who received any aspirin the week before randomization.